SCM
VYNE icon

Soleus Capital Management’s VYNE Therapeutics VYNE Stock Holding History

Soleus Capital Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-703,868
Closed -$1.64M – 100
2023
Q4 		$1.64M Buy
+703,868
New +$2.19M 0.18% 57

Other funds holding VYNE

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $100M AUM
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Soleus Capital Management's VYNE Position: Q1 2024 in Review

Soleus Capital Management sold out of VYNE Therapeutics (VYNE) in Q1 2024, closing a stake of 703,868 shares — an estimated $1.64M sold.

Soleus Capital Management first reported a position in VYNE in Q4 2023 and held it in 1 quarter. The position peaked at $1.64M in Q4 2023. 32 funds tracked by Wall St. Rank hold VYNE as of Q1 2024.

  • Soleus Capital Management reported no remaining VYNE Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Soleus Capital Management sold 703,868 VYNE Therapeutics shares in Q1 2024, an estimated $1.64M.
  • Soleus Capital Management first reported a position in VYNE Therapeutics in Q4 2023 and held it in 1 quarter.
  • Soleus Capital Management's VYNE Therapeutics position peaked at $1.64M in Q4 2023.
  • 32 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2024.

Based on Soleus Capital Management's 13F filing for Q1 2024, filed 15 May 2024.